About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Comparative Formulation Study of Vabicaserin | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT00928551

Comparative Formulation Study of Vabicaserin

This study will compare two different formulations of vabicaserin.

Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18 - 50 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after investigational product administration.
•Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking during the inpatient stay.

Exclusion Criteria

•Use of any investigational or prescription drug within 30 days before investigation product administration.
•Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before study day 1.
•Use of any over-the-counter drugs, including herbal supplements within 72 hours before study day 1.

Related studies

Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities

NCT07059858 · Intellectual Disability, Healthy Subjects

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects

NCT07102251 · Healthy Subjects

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713 · Healthy Participants, Healthy Subjects, and more

RECRUITINGEARLY Phase 1

Single-tracer Multiparametric PET Imaging

NCT06014515 · Healthy Subjects, Cardiovascular Disease

RECRUITINGPhase 1

A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria

NCT07181369 · Healthy Subjects, Cold Urticaria, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 11, 2009Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment15

Start dateJun 2009

Last updatedSep 11, 2009

Condition

Healthy Subjects

Locations shown

Brighton, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 11, 2009Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions